Avotaciclib (trihydrochloride)

• UNSPSC Description:

  Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/avotaciclib-trihydrochloride.html

• Smiles:

  OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3.[H]Cl.[H]Cl.[H]Cl

• Molecular Weight:

  390.66

• References & Citations:

  [1]Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.

• Shipping Conditions:

  Room Temperature

• CAS Number:

  1983984-01-5